Dr. Slaoui had sat on the board of Moderna since 2017. Public officials, including Sen. Elizabeth Warren, D-Mass., have said his position with Moderna would have been a conflict of interest in his new role as head of COVID-19 vaccine development if he was incentivized to favor Moderna’s vaccine.
Moderna told Business Insider that Dr. Slaoui resigned from the board last week and that he will divest his $10 million in stock options.
Read the full article here.
More articles on pharmacy:
32 of 40 drugs deemed critical for COVID-19 in short supply
Gilead strikes deal to manufacture remdesivir for 127 countries
How Civica Rx has responded to drug shortages caused by COVID-19
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
